# Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

> **NCT02229383** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 464 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Exenatide
- **DRUG:** Exenatide matching placebo

## Key facts

- **NCT ID:** NCT02229383
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-06
- **Primary completion:** 2016-08-29
- **Final completion:** 2016-08-29
- **Target enrollment:** 464 (ACTUAL)
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229383, "Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02229383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*